Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation

Figures & data

Table 1 Clinicopathological Characteristics of NSCLC Patients and Expression of miR-183-3p and miR-182-5p in Tumor Tissues

Variables	No. of Cases	miR-183-3p Expression (Median, 25–75 Percentile)	P value	miR-182-5p Expression (Median, 25–75 Percentile)	P value
Ages			0.1184		0.1622
≤65	49	3.566, 2.090–7.035		2.439, 1.004–3.528
>65	27	4.812, 2.768–7.945		2.592, 1.727–5.044
Sex			0.5876		0.6609
Female	28	4.201, 2.114–7.911		2.339, 1.007–4.068
Male	48	4.097, 2.377–6.907		2.543, 1.375–3.970
Histologic type			0.7242		0.7160
LUAD	51	4.537, 2.257–7.261		2.486, 1.065–3.521
LUSC	25	3.980, 2.418–7.708		1.988, 1.379–4.557
Smoking or not			0.3382		0.5850
Non-smoker	38	4.375, 2.486–7.842		2.483, 1.067–4.327
Smoker	37	3.782, 2.217–6.956		2.110, 1.252–3.534
Tumor size (cm)			0.0444*		0.0132*
≤2 cm	18	3.240, 1.116–5.423		1.576, 0.5273–2.620
>2 cm	58	4.746, 2.593–7.794		2.778, 1.436–4.335
Lymphatic metastasis			0.0879		0.5764
Negative	50	4.600, 2.563–7.801		2.413, 1.384–3.724
Positive	26	3.096, 1.680–6.681		2.481, 0.8369–4.239
Distant metastasis			0.5964		0.5407
Negative	71	3.791, 2.337–7.367		2.439, 1.176–3.850
Positive	5	6.001, 3.360–11.99		3.365, 1.175–6.160
Pleura invasion			0.5175		0.2310
Negative	45	3.980, 2.002–7.569		2.110, 0.9606–3.698
Positive	26	4.679, 2.783–7.314		2.861, 1.821–4.239
Vessel carcinoma embolus			0.8313		0.1661
Negative	46	4.600, 2.297–7.350		2.248, 1.067–3.404
Positive	29	3.739, 2.595–8.586		2.704, 1.799–5.275

Note: *Statistically significant, P < 0.05.

Abbreviations: LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

Table 2 Clinicopathological Characteristics of NSCLC Patients and miRNA Expression in Non-Malignant Tissues

Variables	No. of Cases	miR-183-3p Expression (Median, 25–75 Percentile)	P value	miR-182-5p Expression (Median, 25–75 Percentile)	P value
Ages			0.6886		0.6339
≤65	49	0.5603, 0.3221–0.9790		0.3505, 0.1706–0.5907
>65	27	0.5581, 0.4028–1.028		0.4080, 0.2257–0.5334
Sex			0.0935		0.0024*
Female	28	0.4385, 0.3264–0.7317		0.2198, 0.1350–0.4532
Male	48	0.6133, 0.4025–1.145		0.4225, 0.2614–0.6239
Histologic type			0.7789		0.8679
LUAD	51	0.5735, 0.3837–0.9983		0.3743, 0.1768–0.5334
LUSC	25	0.5581, 0.3664–0.9385		0.3354, 0.2156–0.5811
Smoking or not			0.0135*		0.0009*
Non-smoker	38	0.4385, 0.3102–0.7146		0.2330, 0.1430–0.4231
Smoker	37	0.7366, 0.4093–1.276		0.4753, 0.2794–0.6272
Tumor size (cm)			0.0530		0.0270*
≤2 cm	18	0.4329, 0.2661–0.6627		0.2141, 0.1579–0.4047
>2 cm	58	0.5977, 0.4023–1.006		0.4062, 0.2225–0.6093
Lymphatic metastasis			0.4102		0.1271
Negative	50	0.4905, 0.3895–0.8254		0.3307, 0.1683–0.4969
Positive	26	0.5930, 0.3599–1.216		0.4260, 0.1931–0.7117
Distant metastasis			0.3047		0.6841
Negative	71	0.5550, 0.3837–0.9681		0.3505, 0.1772–0.5750
Positive	5	0.9898, 0.4592–1.555		0.4753, 0.2542–0.5512
Pleura invasion			0.3952		0.5720
Negative	45	0.4953, 0.3968–0.7648		0.3354, 0.1770–0.5283
Positive	26	0.7215, 0.3801–0.9906		0.3801, 0.1875–0.5699
Vessel carcinoma embolus			0.1627		0.4707
Negative	46	0.4514, 0.3588–0.8402		0.3549, 0.1642–0.5443
Positive	29	0.7061, 0.4191–0.9940		0.3517, 0.2105–0.5814

Note: *Statistically significant, P < 0.05.

Abbreviations: LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

Figure 1 Relative miR-183-3p or miR-182-5p expression in cancer and normal tissues detected by RT-qPCR. (A and B) Relative miR-183-3p and miR-182-5p expression in cancer and normal tissues of the included patients. **Statistical significance P < 0.01. (C and D) Relative miR-183-3p and miR-182-5p expression in the NSCLC TNM stage I, stage II and stage III+IV groups. (E and F) Relative miR-183-3p and miR-182-5p expression in cancer and normal tissues of different histologic types. (G and H) Figure 1G. Relative miR-183-3p and miR-182-5p expression in cancer and normal tissues of nonsmokers and smokers. *Statistical significance P < 0.05. **Statistical significance P < 0.01.

Abbreviations: LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; ns, no statistical significance.

Figure 2 Relative miR-183-3p or miR-182-5p expression in NSCLC cell lines and BEAS-2B cells detected by RT-qPCR. (A) Relative miR-183-3p expression in various NSCLC cell lines and BEAS-2B cell lines. *Statistical significance P < 0.05. **Statistical significance P < 0.01. (B) Relative miR-182-5p expression in various NSCLC cell lines and BEAS-2B cell lines. **Statistical significance P < 0.01.

Abbreviation: ns, no statistical significance.

Figure 3 Correlation between the relative expression of miR-183-3p and miR-182-5p detected by RT-qPCR. (A) Correlation between relative miR-183-3p expression and relative miR-182-5p expression. (B) Relative miR-182-5p expression in a miR-183-3p overexpression or suppression cell model. H23 or H226 control, H23 or H226 cell lines transfected with RNA-TransMate only. H23 si-miR-183-3p, H23 cell line transfected with the miR-183-3p inhibitor. H226 miR-183-3p OE, H226 cell line transfected with the miR-183-3p mimic. *Statistical significance P < 0.05. **Statistical significance P < 0.01.

Figure 4 Proliferation ability changes in the miR-183-3p overexpression or suppression cell models. (A–C) CCK-8 assays were performed to measure the proliferation abilities of A549, H226 and BEAS-2B cells transfected with the miR-183-3p mimic. miR-183-3p OE, cells transfected with the miR-183-3p mimic. (D) CCK-8 assays were performed to measure the proliferation ability of H1395 cells transfected with the miR-183-3p inhibitor. si-miR-183-3p, cells transfected with the miR-183-3p inhibitor. (E–G) Colony formation assays were conducted to measure the proliferation abilities of A549, H226 and BEAS-2B cells transfected with the miR-183-3p mimic. Significant differences could be observed from representative pictures of culture plates (E), number of colonies (F) and colony formation rate (G). miR-183-3p OE, cells transfected with the miR-183-3p mimic. *Statistical significance P < 0.05. **Statistical significance P < 0.01. (H–J) Colony formation assays were conducted to measure the proliferation ability of H1395 cells transfected with the miR-183-3p mimic. Significant differences could be observed from representative pictures of culture plates (H), number of colonies (I) and colony formation rate (J). si-miR-183-3p, cells transfected with the miR-183-3p inhibitor. *Statistical significance P < 0.05.

Abbreviation: Control, corresponding negative control.

Figure 5 Bioinformatics analysis of the clinicopathological significance and prognostic value of miR-183-3p in TCGA database. (A–C) Relative miR-183-3p expression among different tumor sizes (A), histological types (B) and smoking histories (C). **Statistical significance P < 0.01. (D–F) Kaplan-Meier curves of NSCLC cases in TCGA database stratified by miR-183-3p expression (bottom 10% [n = 96] versus top 10% [n = 96]) (D). Further respective analysis in LUAD cases (E) and LUSC cases (F) showed different prognostic value.

Abbreviations: LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.